Introgen Therapeutics Inc will update its progress in the development of Advexin and INGN 241 at the 95th annual meeting of the American Association of Cancer Research (AACR) held in Orlando, Florida. Advexin currently is in phase 3 trials for the treatment of head and neck cancer and INGN 241 is being evaluated in phase 1 and phase 2 clinical trials for multiple tumor types.
Nine abstracts related to Introgen's drug candidates will be presented during the conference, which will be held March 27 - March 31, 2004. Two INGN 241 abstracts will be presented on March 28; two on Tuesday, March 30 and four on Wednesday, March 31. One Advexin abstract will be presented on Tuesday, March 30.
Introgen is a leading developer of biopharmaceutical products designed to induce therapeutic protein expression using non-integrating gene agents for the treatment of cancer and other diseases. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates a commercial-scale, CGMP manufacturing facility.